Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 4/20 | 0.31 |
| ▸ | MMP1 | P03956 | 3/20 | 0.31 |
| ▸ | MMP9 | P14780 | 3/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228145 | 0.86 | KCNH2 (0.43) | KCNH2CHRM1PTGS1SLC6A2SLC6A4 | |
| SCHEMBL1227410 | 0.83 | KCNH2 (0.44) | KCNH2CHRM1PTGS1SLC6A2SLC6A4 | |
| SCHEMBL1228745 | 0.80 | KCNH2 (0.45) | KCNH2CHRM1PTGS1SLC6A2SLC6A4 | |
| SCHEMBL12901287 | 0.76 | CASR (0.39) | MMP2MMP1MMP9ALDH1A1MMP3 | |
| SCHEMBL12901288 | 0.74 | CASR (0.38) | MMP2MMP1MMP9MCHR1ALDH1A1 | |
| SCHEMBL1228793 | 0.74 | PKM (0.33) | ALDH1A1 | |
| SCHEMBL1227909 | 0.73 | CHRM1 (0.45) | KCNH2CHRM1PTGS1SLC6A2SLC6A4 | |
| SCHEMBL16319550 | 0.72 | KCNH2 (0.32) | KCNH2ALDH1A1 | |
| SCHEMBL1228920 | 0.71 | PKM (0.33) | ALDH1A1 | |
| SCHEMBL1228757 | 0.70 | CHRM1 (0.44) | KCNH2CHRM1PTGS1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | KCNH2 2847/4885CHRM1 1308/4885PTGS1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.